Determination of the genetic bacteria count of Akkermansia, Bacteroides, Bifidobakterium, Faecalibacterium et al.
An adult human being is settled by about 1014 bacteria (100 trillion!), not only, but predominantly in the gastrointestinal tract. The intestinal microbiota is a complex community of microorganisms in the gut and is unique like a fingerprint to each human. It begins with the first colonisation in early childhood and its composition depends largely on the diet.
These colonising bacteria take over important functions for the utilisation of food, for instance the synthesis of vitamins B1, B2, B6, B12 and K and certain short-chain fatty acids, which in turn serve the intestinal mucosal cells as an energy source. Changes in the composition of the intestinal microbiota – also called a dysbiosis - may be associated with diseases, e. g. systemic inflammations such as a chronic inflammatory bowel disease or a reduced colonisation resistance, autoimmune diseases such as rheumatoid arthritis or allergies, metabolic diseases such as obesity or metabolic syndrome, type 2 diabetes or non-alcoholic fatty liver. The more diversity and species-richness the intestinal microbiota shows, the better the digestive system and the body's own defense function. It is noteworthy in that context that increased use of antibiotics in adolescence adversely affects this diversity.
The intestinal microbiome means the entirety of the intestinal flora genes found in the intestinal flora. The genetic analysis of the microbiome and the determination of - proportionate - composition of the intestinal flora are therefore an important diagnostic tool whose value is increasingly acknowledged.
Protective bacteria metabolise carbohydrates, produce vitamins and short-chain fatty acids and stabilise the intestinal barrier - for example Bifidobacteria, Lactobacilli, various genera of Bacteroidetes and as well E. coli. Harmful bacteria form lipopolysaccharides as well as toxins and may lead to chronic systemic inflammation – for example clostridia.
In obesity, the ratio of Firmicutes to Bacteroidetes plays a significant role. The higher the proportion of Bacteroidetes, the lower the body weight. An excess of Firmicutes promotes obesity as well as a deficiency of Faecalibacterium prausnitzii and Akkermansia muciniphila. These two are significantly reduced in obesity, and this deficiency as well correlates with an increased risk for the development of intestinal tumors.
Once the diseases or symptoms listed above have occurred, a molecular biology analysis of gut microbiota can better measure the effects of the individual microbiota on colonisation resistance, digestive processes, vitamin synthesis, or immune system effects than cultural breeding, as anaerobic bacteria are quite difficult to cultivate.
Molecular genetic diagnosis allows the analysis of the diversity of the microbiome and statements on dysbiosis, it quantifies the existing bacterial strains and can determine the Firmicutes / Bacteroides ratio.
Only with this examination, an adapted therapy can be started, for instance a specific adapted diet with pre- and probiotics.
MutaPLATE® Akkermansia, PCR KE19007
MutaPLATE® Bacteroides, PCR KE19001
MutaPLATE® Bifidobakterien, PCR KE19003
MutaPLATE® Eubakterien, PCR KE19002
MutaPLATE® Faecalibacterium, PCR KE19011
NEW: MutaPLEX® AKM/FAEP KG1911-96
NEW: MutaPLEX® BAC/EU/BIF KG11912-96
(Bacteroides, Eubacterium, Bifidobacterium)